Can learning to manage stress ease the burden of myasthenia gravis?
NCT ID NCT07512375
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aims to see if a stress management program can help adults with myasthenia gravis feel less anxious and stressed, and improve their quality of life. About 62 participants will take part in an 8-session program and report their symptoms before and after. The goal is to find out if this approach is helpful and practical for people living with this chronic condition.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 62 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Apr 2026
An estimate. Start dates often move.
- Expected to finish
-
Jun 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Adults living with myasthenia gravis followed at University Hospital Grenoble Alpes.
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Participant is aged 18 years or over (legal age of majority under French law). * Participant has freely provided their non-opposition to participate in the study. * Participant has a confirmed diagnosis of Myasthenia Gravis. * Participant has sufficient proficiency in both spoken and written French to complete assessments and questionnaires, attend the programme sessions, and carry out home-based exercises. Exclusion Criteria: * Participant presenting with one or more severe and established psychiatric disorders (e.g. severe depression, psychosis) that could interfere with the study's conduct, particularly the assessment of the primary and secondary endpoints. * Participant presenting with another chronic condition that induces fatigue. Protected persons (as defined by Articles L1121-5 to L1121-8 of the French Public Health Code \[CSP\]).
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Myasthenia gravis (MG) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Smartwatches and video exams: a new way to predict MG Flare-Ups?
- Can tracking daily life unlock myasthenia gravis mysteries?
- Hidden toll of myasthenia gravis: study probes sexual and bladder problems often overlooked
- Engineered immune cells take aim at autoimmune diseases
- New drug aims to ease daily struggles of myasthenia gravis
- New drug MTM-H-001 targets B-Cell autoimmune diseases in early trial